

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA

**Talazoparib with enzalutamide for untreated hormone-
relapsed metastatic prostate cancer**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final appraisal determination

(when a draft guidance consultation issued)

1.	Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?
No.	

2.	If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
After consultation, the intervention was recommended for an optimised population of people with hormone-relapsed metastatic prostate cancer where chemotherapy is not clinically indicated, and abiraterone plus prednisolone is not tolerated or there are clinical conditions that preclude the use of abiraterone plus prednisolone. However, the recommendation does not affect access for specific groups based on protected characteristics. .	

3.	If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No.	

4.	If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?
N/A.	

5.	Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
Yes, section 3.17.	

Approved by Associate Director: Emily Crowe.....

Date: 15/01/2026